Evidence map›Paper›PMID 26981940›Full record

ArticleThe New England journal of medicine2016

Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.

Bernard Zinman, John M Lachin, Silvio E Inzucchi

7 registry-linked trialsAbstract readLetterComment
PubMed Publisher
In one paragraph

Article in The New England journal of medicine, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It reports registered trial NCT02964715. Cited by 163 papers, 11 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
163citing papers in PubMed, 11 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02964715 phase4unknown status

The Effect of Empagliflozin on NAFLD in Asian Patients With Type 2 Diabetes

Ran2016Enrolled25Registered outcomes17Posted comparisons0ConditionsNAFLD, Type2 DiabetesArmsempagliflozin
PMID 15915461PMID 27289126PMID 26856933PMID 27462372PMID 26785389PMID 25685689PMID 23840612PMID 23707905PMID 20207596other papers from this trial
Open the trial in the graph
NCT03132181 phase2completedstarted 2017, after this paper: background citation

Empagliflozin as a Modulator of Systemic Vascular Resistance and Cardiac Output in Patients With Type 2 Diabetes

Ran2017Enrolled40Registered outcomes14Posted comparisons0ConditionsDiabetes Mellitus Type 2 (T2DM)Armsempagliflozin, Placebo
PMID 24939043PMID 24444522PMID 26343814PMID 23735727PMID 24475922PMID 27299675PMID 24026259other papers from this trial
Open the trial in the graph
NCT04203927 early_phase1unknown statusstarted 2020, after this paper: background citation

Effects of Empagliflozin on Cardiac Microvasculature and Insulin Sensitivity in Subjects With Type 2 Diabetes

Ran2020Enrolled50Registered outcomes4Posted comparisons0ConditionsInsulin Sensitivity, Type2 DiabetesArmsempagliflozin 25 mg
PMID 29166232PMID 25633683PMID 27299675PMID 24711523PMID 23459195PMID 21617098PMID 21047922PMID 20978231PMID 20380649PMID 19996061PMID 16386091PMID 16308832other papers from this trial
Open the trial in the graph
NCT04906213 phase2terminatedstarted 2022, after this paper: background citation

CardioRenal Effects of SGLT2 Inhibition in Kidney Transplant Recipients

Ran2022Enrolled20Registered outcomes10Posted comparisons0ConditionsDiabetes Mellitus, Type 2, Kidney Transplant; ComplicationsArmsEmpagliflozin10Mg Tab, Placebo
PMID 28605608PMID 25081992PMID 27470878PMID 30415602PMID 30862658other papers from this trial
Open the trial in the graph
NCT05719714 phase1 / phase2active not recruitingstarted 2024, after this paper: background citation

Effect of Dapagliflozin on Metabolomics and Cardiac Mechanics in Chronic Kidney Disease

Ran2024Enrolled18Registered outcomes5Posted comparisons0ConditionsChronic Kidney Diseases, Heart Failure, Heart Failure With Preserved Ejection Fraction, Kidney DiseasesArmsDapagliflozin 10 MG [Farxiga]
PMID 29166232PMID 29526832PMID 29133604PMID 29762782PMID 10716471PMID 15504931PMID 16461840PMID 18760751PMID 21262990PMID 21817129PMID 24218128PMID 25370599other papers from this trial
Open the trial in the graph
NCT03936660 nacompletednot on this mapstarted 2019, after this paper: background citation

COOrdinating CaRDIology CliNics RAndomized Trial of Interventions to Improve OutcomEs (COORDINATE) - Diabetes

TypeinterventionalSponsorDuke UniversityRan2019 to 2022Enrolled1,049ConditionsDiabetes Mellitus, Type 2, Cardiovascular DiseasesArmsIntense Education Intervention
NCT03965000 unknown statusnot on this mapstarted 2019, after this paper: background citation

Human SLC5A2 Deficiency and the Glucagon-Incretin Axis: A Pilot Study

TypeobservationalSponsorMedical University InnsbruckRan2019 to 2022Enrolled10ConditionsFamilial Renal Glucosuria, Diabetes Mellitus, Cardiovascular DiseasesArmsMixed-meal-tolerance-test
3 · Its place in the literature

Who cites it

163 citing papers in PubMed, 11 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Guideline
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Pooled it
  11. Pooled it
  12. Trial
  13. Trial
  14. Trial
  15. Trial
  16. Trial
  17. Trial
  18. Trial
  19. Trial
  20. Trial

103 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

3 authors.

Bernard Zinman
John M Lachin
Silvio E Inzucchi

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Benzhydryl CompoundsCardiovascular DiseasesDiabetes Mellitus, Type 2FemaleGlucosidesHumansHypoglycemic AgentsMaleBenzhydryl CompoundsGlucosidesHypoglycemic Agents

Identifiers

PMID26981940

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

and 1 more above

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.